Rising Temperatures Increase Risk for Poor Maternal, Neonatal Outcomes
By Lori Solomon HealthDay Reporter
TUESDAY, Nov. 19, 2024 -- Escalating heat exposure poses a major threat to maternal and neonatal health, according to a review published online Nov. 5 in Nature Medicine.
Darshnika P. Lakhoo, M.B.Ch.B., M.P.H., from University of the Witwatersrand in Johannesburg, South Africa, and colleagues conducted a systematic literature review to assess heat impacts on maternal, fetal, and neonatal health.
Based on 198 studies (66 countries), the researchers found increased odds of preterm birth per 1 degree Celsius increase in heat exposure (odds ratio [OR], 1.04; 12 studies) and during heatwaves (OR, 1.26; 10 studies). High heat exposure was also associated with an increased risk for stillbirths (OR, 1.13; nine studies), congenital anomalies (OR, 1.48; six studies), and gestational diabetes mellitus (OR, 1.28; four studies). During heatwaves, the odds of any obstetric complication increased 25 percent (11 studies). Conditions showed variance in susceptibility windows. Overall, heterogeneity in exposure metrics and study designs limited findings.
"This is a pivotal moment for public health and climate action. Protecting the health of pregnant women and newborns must become a priority in our response to climate change," Lakhoo said in a statement. "We hope these findings will catalyze change at the policy level, ensuring at-risk populations receive the support they need."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-21 00:00
Read more
- Health Span-Lifespan Gaps Widening Globally
- Trump Says He'll Try to Rid U.S. of Daylight Saving Time
- Even Minutes-Long Exercise 'Bursts' Can Help Women's Hearts
- 1990 to 2021 Saw Decline in Life Expectancy in the United States
- New Weight-Loss Advance: A Gastric Balloon You Control to Feel Full or Not
- FDA Approves Zepbound (tirzepatide) as the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions